Composition for preventing or treating head and neck cancer comprising P-cadherin siRNA and c-MET inhibitor as effective component
The combination of P-cadherin siRNA and a c-MET inhibitor effectively addresses the limitations of current head and neck cancer treatments by significantly reducing cancer cell growth, migration, and invasion, offering a promising therapeutic approach.
Patent Information
- Application Number
- KR1020230139723
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-10-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-10-18
AI Technical Summary
Current treatments for head and neck cancer, including surgery, radiation therapy, and chemotherapy, have not significantly improved survival rates over the past 30 years, and there is a need for more effective compositions that can inhibit the growth, migration, and invasion of head and neck cancer cells.
A pharmaceutical composition comprising P-cadherin siRNA and a c-MET inhibitor, such as SU11274, is used to treat head and neck cancer, demonstrating significant reduction in cancer cell growth, migration, and invasion in cell lines and animal models.
The combination of P-cadherin siRNA and SU11274 significantly reduces head and neck cancer cell proliferation, migration, and invasion, as shown by WST-1 analysis, colony formation assays, and xenograft models, indicating potential for improved treatment efficacy.
Smart Images

Figure 112023114428920-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET inhibitor as active ingredients. Background Technology
[0002] Head and neck cancer is known to be the sixth most common cancer worldwide, with approximately 600,000 cases occurring annually. The head and neck region refers to the area between the brain and the upper chest. This region contains numerous organs responsible for functions such as eating and voice production, including the nasal cavity, tongue, mouth, larynx, and salivary glands; cancers that develop in these organs are collectively referred to as head and neck cancer. Due to the unique characteristics of the face and neck compared to cancers of other organs, head and neck cancer presents significant treatment limitations. Furthermore, it is often fatal once it progresses and frequently results in functional or cosmetic disabilities after treatment. The pathological origins of the disease are diverse, and even within the same pathology, the prognosis varies significantly depending on the location of occurrence. With the aging population and the rise in alcohol consumption and smoking, the incidence of head and neck cancer is on the rise. It accounts for 4–5% of all cancers; statistically, it ranks 7th in incidence by organ and 5th among male patients, classifying it as a relatively common cancer. Specifically examining the types of head and neck cancer, they broadly include nasal and paranasal sinus cancer, oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, cervical and esophageal cancer, salivary gland cancer, salivary gland cancer, malignant lymphoma, malignant melanoma, and various soft tissue cancers.
[0003] Surgery, radiation therapy, and chemotherapy are the primary treatment methods for head and neck cancer. Since head and neck cancer often progresses to an advanced stage, combination therapies involving two or more treatments are typically employed. While it is common practice to add radiation therapy or chemoradiation therapy after surgery, recently, in cases where severe postoperative dysfunction is anticipated due to the sacrifice of major organs such as the larynx, organ-sparing treatment methods are being utilized. These methods involve either re-selecting surgery or radiation therapy based on the tumor's response to chemotherapy, or administering chemoradiation therapy first to decide on surgery later. In other words, while the most critical aspect of head and neck cancer treatment is eliminating the cancer completely to increase survival rates, preserving the voice—a vital function of the oral cavity, tongue, and larynx—is also considered important as it plays a significant role in the patient's quality of life after treatment. Although the field of head and neck cancer treatment has achieved remarkable growth in recent years, survival rates have not shown a distinct improvement over the past 30 years, despite advancements in treatment technology.
[0004] Prior art related to head and neck cancer includes Korean Published Patent No. 2021-0129789, which discloses a 'composition for the prevention, improvement, or treatment of head and neck cancer containing moscatillin as an active ingredient,' and Korean Published Patent No. 2023-0039230, which discloses a 'pharmaceutical composition for the combined administration of melatonin and verteporfin for the treatment of head and neck cancer.' However, there has not yet been any disclosure regarding the 'composition for the prevention or treatment of head and neck cancer containing P-cadherin siRNA and a c-MET inhibitor as active ingredients' of the present invention. The problem to be solved
[0005] The present invention was derived from the above-mentioned needs, and the present invention provides a composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase Met) inhibitor as active ingredients. More specifically, the present invention was completed by confirming that when P-cadherin siRNA, a cell adhesion protein, and SU11274, a c-MET inhibitor, were treated in combination in head and neck cancer cell lines and animal models, the growth, migration, and invasion of head and neck cancer cells were significantly reduced compared to when P-cadherin siRNA and SU11274 were treated individually. means of solving the problem
[0006] To solve the above problem, the present invention provides a pharmaceutical composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor as active ingredients.
[0007] In addition, the present invention provides a veterinary composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor as active ingredients.
[0008] In addition, the present invention provides a method for preventing or treating head and neck cancer comprising the step of administering P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor to an individual other than a human. Effects of the invention
[0009] The present invention relates to a composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase Met) inhibitor as active ingredients. More specifically, when P-cadherin siRNA, a cell adhesion protein, and SU11274, a c-MET inhibitor, are treated in combination in head and neck cancer cell lines and animal models, the growth, migration, and invasion of head and neck cancer cells are significantly reduced compared to when P-cadherin siRNA and SU11274 are treated individually. Brief explanation of the drawing
[0010] Figure 1 shows the results of confirming the cell proliferation inhibitory effect through WST-1 analysis when the P-cadherin siRNA and SU11274 of the present invention were combined and treated on hypopharyngeal cancer cells (SNU1041) (A) and laryngeal cancer cells (SNU1076) (B). NCsiR is the negative control, P-cadsiR is the group treated with P-cadherin siRNA alone, SU11274 is the group treated with SU11274, a c-MET (tyrosine-protein kinase met) inhibitor, alone, and P-cadsiR+SU11274 is the group treated with P-cadherin siRNA and SU11274 in combination. ** and *** indicate that the cell proliferation ability of the group treated with P-cadherin siRNA and SU11274 in combination was statistically significantly lower compared to the group treated with P-cadherin siRNA alone or SU11274 alone, with ** being p<0.01 and *** being p<0.001. Figure 2 shows the results of confirming the cell proliferation inhibitory effect through a colony formation assay when the P-cadherin siRNA and SU11274 of the present invention were combined and treated with hypopharyngeal cancer cells (SNU1041) (A) and laryngeal cancer cells (SNU1076) (B). Figure 3 shows the results of confirming the degree of cell migration when hypopharyngeal cancer cells (SNU1041) were treated with the P-cadherin siRNA and SU11274 of the present invention in combination. A is a photograph taken with an optical microscope, and B is a graph quantifying this. * and *** indicate that the proportion of migrated cells in the group treated with P-cadherin siRNA and SU11274 in combination was statistically significantly lower compared to the groups treated with P-cadherin siRNA alone or SU11274 alone, where * is p<0.05 and *** is p<0.001. Figure 4 shows the results of confirming the degree of cell migration when laryngeal cancer cells (SNU1076) were treated with the P-cadherin siRNA and SU11274 of the present invention in combination. A is a photograph taken with an optical microscope, and B is a graph quantifying this. * and ** indicate that the proportion of migrated cells in the group treated with P-cadherin siRNA and SU11274 in combination was statistically significantly lower compared to the groups treated with P-cadherin siRNA alone or SU11274 alone, where * is p<0.05 and ** is p<0.01. Figure 5 shows the results of confirming the degree of cell infiltration using an optical microscope when hypopharyngeal cancer cells (SNU1041) (A) and laryngeal cancer cells (SNU1076) were treated with the P-cadherin siRNA and SU11274 of the present invention. Figure 6 shows the results confirming the growth inhibitory effect on head and neck cancer cells when the P-cadherin siRNA and SU11274 of the present invention were treated in combination in a xenograft model. A is a tumor image tracked by IVIS (In Vivo Optical Imaging System) after injecting luciferase-expressing FaDu (FaDu-Luc) cells into mice; B is a graph quantifying the luminescence intensity of the tumor's ROI (Region of Interest); C is a photograph showing the measured tumor size; and D is a graph showing the tumor volume measured every 3 days for 18 days. *, **, *** represent the P-cadherin siRNA alone treatment group; SU11274 alone treatment group; compared to the negative control group (NCsiR) with no treatment. Or, the total flux or tumor volume of the group treated with P-cadherin siRNA and SU11274 in combination was statistically significantly reduced, where * is p<0.05, ** is p<0.01, and *** is p<0.001. #, ##, and ### indicate that the total flux or tumor volume of the group treated with P-cadherin siRNA and SU11274 in combination was statistically significantly reduced compared to the group treated with P-cadherin siRNA alone or SU11274 alone, where # is p<0.05, ## is p<0.01, and ### is p<0.001. Specific details for implementing the invention
[0011] To achieve the objective of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor as active ingredients.
[0012] In the pharmaceutical composition for the prevention or treatment of head and neck cancer according to the present invention, the P-cadherin siRNA is preferably an oligonucleotide composed of SEQ ID NO. 1 and SEQ ID NO. 2, but is not limited thereto.
[0013] The 'siRNA (small interfering RNA)' used in the present invention refers to a short double-stranded RNA capable of inducing RNAi (RNA interference) phenomena through the cleavage of specific mRNA. It consists of a sense RNA strand having a sequence homologous to the mRNA of a target gene and an antisense RNA strand having a sequence complementary thereto. Since siRNA can suppress the expression of a target gene, it is provided as an efficient gene knockdown method or as a method for gene therapy.
[0014] In the siRNA according to the present invention, the sense RNA strand and / or antisense RNA strand may include at least one chemical modification within its sugar portion, nucleobase portion, or internucleotide structure. Such modification may enable the inhibition of the degradation of the siRNA by nucleases in vivo. Any chemical modification capable of enhancing the stability and biocompatibility of the siRNA according to the present invention in vivo is included within the scope of the present invention. The siRNA according to the present invention is "isolated," which means not existing in a natural state but can be obtained by any means involving human intervention. In particular, the siRNA according to the present invention may be obtained by chemical synthesis, amplification of the required nucleotide sequence by polymerase chain reaction (PCR), or purification of an already existing siRNA by recombinant synthesis.
[0015] The siRNA according to the present invention may additionally comprise a 3' overhang fragment of 2 to 4 nucleotides in addition to the sense and / or antisense RNA strands. As used herein, the expression "3' overhang fragment of 2 to 4 nucleotides" is understood to be present on at least one strand of an RNA duplex of 2 to 4 nucleotides that is not paired with the complementary strand at the 3' distal end of one strand. The nucleotides used for the 3' overhang fragment may be natural nucleotides (ribonucleotides or deoxyribonucleotides) or modified nucleotides such as LNA (Locked Nucleic Acid) containing a methylene bridge between the 2' and 4' positions of ribose. Additionally, the 3' overhang fragment may have any form of chemical modification described in the paragraphs relating to the sense RNA strand and / or antisense RNA strand of the siRNA according to the present invention. The preferred sequence for the 3' overhang fragment consists of a consecutive sequence of T (where T is deoxythymidine) or U (where U is uracil), preferably a consecutive sequence of T. Additionally, the sequence length of the 3' overhang fragment is two consecutive nucleotide bases, preferably "TT" or "UU" (where U is uracil). Also, preferably, both complementary strands of the siRNA of the present invention contain a 3' overhang fragment. In this case, the lengths and sequences of the two 3' overhang fragments may be the same or different. Preferably, both complementary strands of the siRNA according to the present invention may contain two identical 3' overhang fragments of nucleotides having the sequence "TT". Such a 3' overhang fragment serves as an additional component advantageous for cell conjugation without interfering with binding to the target sequence.
[0016] The above c-MET inhibitor may be SU11274{(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide}, but is not limited thereto.
[0017] The above-mentioned P-cadherin siRNA and c-MET inhibitors may inhibit the proliferation, migration, and invasion of head and neck cancer cells, but are not limited thereto.
[0018] The head and neck cancer mentioned above may be any one cancer selected from the group consisting of nasal cavity cancer, paranasal sinus cancer, oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, cervical esophageal cancer, salivary gland cancer, salivary gland cancer, and tongue cancer, and preferably may be hypopharyngeal cancer and laryngeal cancer, but is not limited thereto.
[0019] The composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents in addition to the active ingredient, and may be in various oral or parenteral formulations. When formulating, it is prepared using commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, and other diluents or excipients. Solid formulations for oral administration include capsules, powders, granules, tablets, pills, etc., and these solid formulations are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition, lubricants such as magnesium stearate and talc are also used in addition to simple excipients. Liquid formulations for oral administration include suspensions, emulsions, syrups, and aerosols; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, Macrogol, Tween 61, cocoa dough, laurin dough, and glycerogelatin may be used as bases for suppositories. For parenteral administration, it is preferable to select a method of topical application or injection via the abdominal cavity, rectum, vein, muscle, subcutaneous, intrauterine dura mater, or cerebrovascular system.
[0020] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the level of the effective amount may be determined according to factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above-mentioned factors into account, and this can be easily determined by a person skilled in the art.
[0021] The dosage of the composition of the present invention varies depending on the patient's body weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modulators.
[0022] In addition, the present invention provides a veterinary composition for the prevention or treatment of head and neck cancer comprising P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor as active ingredients.
[0023] The veterinary composition of the present invention may further include suitable excipients and diluents according to conventional methods. Examples of excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
[0024] The veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using methods well known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc.
[0025] The effective amount of the veterinary composition according to the present invention can be appropriately selected according to the individual animal. It may be determined based on the severity of the disease or condition, the sensitivity to the active ingredient of the present invention according to the individual's age, weight, health status or gender, the route of administration, the duration of administration, factors including other compositions combined with or used simultaneously with the composition, and other factors well known in the physiological or veterinary field.
[0026] In addition, the present invention provides a method for preventing or treating head and neck cancer comprising the step of administering P-cadherin siRNA and a c-MET (tyrosine-protein kinase met) inhibitor to an individual other than a human.
[0027] The present invention will be described in detail below by way of embodiments. However, the following embodiments are merely illustrative of the present invention, and the scope of the present invention is not limited to the following embodiments.
[0028] [Materials and Methods]
[0029] 1. Cell culture
[0030] Human head and neck squamous cell carcinoma (HNSCC) cell lines SNU1076 (laryngeal cancer) and SNU1041 (hypopharyngeal cancer) were purchased from the Korea Cell Line Bank. SNU1076 and SNU1041 cell lines were cultured in RPMI 1640 medium (WELGENE Inc., Korea). All cell lines were cultured in 10% FBS (fetal bovine serum, HyClone TM , USA) and 100 U / mL of penicillin-streptomycin (HyClone™, USA) were added, and the mixture was cultured at 37°C under 5% CO2 conditions.
[0031] 2. P-Cadherin siRNA (Small-interfering RNA) transfection
[0032] siRNA transfection is Lipofectamine TM The procedure was performed using RNAi MAX (Thermo-Fisher Scientific, USA). Lipofectamine was administered to SNU1076 (laryngeal cancer) and SNU1041 (hypopharyngeal cancer) cell lines. TM 50 nM of P-cadherin siRNA (Table 1; Bioneer, Cat # 1001-1) and a negative control (NCsiRNA; #SN-1003, Bioneer, South Korea) were transfected using RNAi MAX.
[0033] siRNA sequence for P-cadherin siRNA Sequence (5'→3') Sequence number P-Cadherin sense CUC UCU GGA AUG GAA CCU U 1 antisense AAG GUU CCA UUC CAG AGA G 2
[0034] 3. Cell proliferation analysis
[0035] 1 × 10 per well in a 96-well plate 4 After 24 hours of cell inoculation, SNU1076 (laryngeal cancer) and SNU1041 (hypopharyngeal cancer) cells were treated with P-cadherin siRNA (50 nM) alone; the c-MET inhibitor SU11274 (CAS no. 658084-23-2, 5 μM) alone; or a combination of P-cadherin siRNA (25 nM) and SU11274 (2.5 μM); cultured for 48 hours, and the cell viability of SNU1076 and SNU1041 was measured using the WST-1 (Roche Diagnostics Corporation, Indianapolis, USA) assay. The WST-1 assay measures the number of living cells by measuring the chromogenic substance called formazan in WST (Tetrazolium Salt), a dehydrogenase present in the mitochondria of living cells. The formazan product was quantitatively measured at 450 nm using an ELISA (Enzyme-linked immunosorbent assay).
[0036] 4. Colony Formation Analysis
[0037] 1 × 10 per well in a 6-well plate 3 After inoculating the cells, they were treated with P-cadherin siRNA (50 nM) alone; the c-MET inhibitor SU11274 (CAS no. 658084-23-2, 5 μM) alone; or a combination of P-cadherin siRNA (25 nM) and SU11274 (2.5 μM); cultured for 48 hours, and then grown for 12 days with the medium replaced every 3 days. Colonies were fixed with 4% formaldehyde, stained with crystal violet, and then imaged and counted.
[0038] 5. Analysis of cell migration and invasion
[0039] Cell migration and invasion were analyzed using a Transwell chamber (Corning Coster, Cambridge, MA) equipped with a 6.5 mm diameter polycarbonate filter (8 μm pore size). Briefly, for invasion analysis, the Transwell membrane was coated with Matrigel (BD Biosciences) at 37°C for 6 hours, and for migration analysis, it was coated without Matrigel. 2 × 10⁶ cells contained in 100 μl of serum-free medium were placed in the upper chamber. 5 Cells were added, and 700 µl of medium containing 10% FBS was added to the lower chamber. Subsequently, the cells were treated with P-cadherin siRNA (50 nM) alone; the c-MET inhibitor SU11274 (CAS no. 658084-23-2, 5 μM) alone; or a combination of P-cadherin siRNA (25 nM) and SU11274 (2.5 μM), and cultured for 48 hours at 37°C and 5% CO2. Finally, non-migrating or non-infiltrating cells were removed using a cotton swab, cells attached to the lower chamber (migrating or infiltrating cells) were stained with crystal violet, and counted in four representative regions under a light microscope (200x magnification).
[0040] 6. Xenotransplantation in vivo Tumor model (Xenograft in vivo tumor model)
[0041] Mice were maintained under specific pathogen-free conditions and used in accordance with the guidelines of the Institutional Animal Care Committee of Chungnam National University; the animal research protocol (Protocol No.: CNUH-020-A0036-1) was approved by the Committee. Twenty 6-week-old BALB / c-nude mice were purchased from Orient Bio Co., Ltd., and the mice were randomly divided into four experimental groups (n=5): a negative control group (NCsiR); a group treated with P-cadherin siRNA alone (P-cadsiR, 2 mg / 100 µl); a group treated with SU11274 alone (SU11274, 0.4 mg / 100 µl); and a group treated with P-cadherin siRNA and SU11274 in combination (1 mg P-cadsiR + 0.2 mg SU11274 / 100 µl). Luciferase-expressing FaDu (FaDu-luc) cells (1×10⁶ 6 ) was subcutaneously inoculated into the right lower flank of BALB / c-nude mice. Seven days after inoculation, when the tumor diameter reached approximately 50 mm, 100 µl of each treatment group was administered via intratumoral injection once every three days for 18 days. After the last injection, tumors were excised from mice that had been euthanized and used for histological analysis.
[0042] 7. Immunohistochemistry analysis
[0043] Tissue samples were fixed with a 4% formalin solution and embedded in paraffin. For hematocillin and eosin (H&E) staining, tissue sections were deparaffinized in xylene, hydrated in an alcohol solution, and stained with H&E. After mounting, the samples were examined using an automated digital slide scanner (Pannoramic MIDI; 3DHISTECH, HU). For immunohistochemistry, tissue sections were deparaffinized in xylene, hydrated in an alcohol solution, and heated at 100°C for 15 minutes in antigen recovery Citra solution (pH 6.0) for antigen recovery. For monostaining, endogenous peroxidase activity was blocked for 30 minutes at room temperature in a 1% (v / v) hydrogen peroxide solution (Sig-ma-Aldrich, USA) diluted with phosphate-buffered saline (PBS) containing 0.3% Triton X-100. Sections were incubated overnight at 4°C with labeled antibodies, followed by incubation with a secondary antibody conjugated with HRP (horseradish peroxidase). Finally, labeled antibodies were detected using 3,3'-diaminobenzidine (DAB, USA), and nuclei were stained with hematoxylin. After washing with PBS, the samples were analyzed using an automated digital slide scanner.
[0044] 8. Statistical Processing
[0045] Statistical analysis was performed using SPSS for Windows statistical software (version 20.0; SPSS Inc., Chicago, IL, USA). All experiments were repeated three times, and statistical significance between groups was analyzed using the unpaired Student's t-test. Data were expressed as mean ± standard deviation, p < 0.05 was considered to indicate statistical significance(*: p < 0.05, **: p< 0.01, ***: p < 0.001).
[0046] Example 1. Growth inhibitory effect of combined treatment with P-cadherin siRNA and SU11274 on head and neck cancer cells
[0047] When the P-cadherin siRNA and SU11274 (c-Met inhibitor) of the present invention were combined and treated with hypopharyngeal cancer (SNU1041) and laryngeal cancer (SNU1076) cells, cell proliferation ability was measured through WST-1 and colony formation analysis.
[0048] As a result, as disclosed in Fig. 1, the proliferative capacity of hypopharyngeal and laryngeal cancer cells was statistically significantly reduced in the combined treatment group of P-cadherin siRNA (P-cadsiR) and SU11274 of the present invention compared to the single treatment groups of P-cadherin siRNA (P-cadsiR) and SU11274, respectively. In addition, the results of the colony formation analysis also showed that the number of colonies decreased in the combined treatment group of P-cadherin siRNA (P-cadsiR) and SU11274 of the present invention compared to the single treatment group (Fig. 2).
[0049] Example 2. Inhibitory effect of combined treatment with P-cadherin siRNA and SU11274 on the migration and invasion of head and neck cancer cells
[0050] To measure the ability to inhibit the migration and invasion of cancer cells when the P-cadherin siRNA and SU11274 (c-Met inhibitor) of the present invention were combined and treated with hypopharyngeal cancer (SNU1041) and laryngeal cancer (SNU1076) cells, an analysis was performed using a matrigel coating chamber.
[0051] As a result, as disclosed in Figures 3 and 4, the degree of migration of hypopharyngeal and laryngeal cancer cells in the combined treatment group of P-cadherin siRNA and SU11274 was statistically significantly reduced compared to the single treatment groups of P-cadherin siRNA and SU11274, respectively, and it was confirmed that the inhibitory effect on cancer cell invasion was also superior in the combined treatment group of P-cadherin siRNA (P-cadsiR) and SU11274 compared to the single treatment group (Figure 5).
[0052] Example 3. Growth inhibitory effect of combined treatment with P-cadherin siRNA and SU11274 on head and neck cancer cells in a xenograft model
[0053] Inside the body ( in vivo In order to determine the effect of combined treatment with P-cadherin siRNA and SU11274 on cancer growth, luciferase-expressing FaDu (FaDu-Luc) cells were subcutaneously inoculated into 6-week-old BALB / c nude mice, and after 7 days, when the tumor diameter was approximately 50 mm, P-cadherin siRNA alone; SU11274 alone; or P-cadherin siRNA and SU11274 combined treatment were injected every 2 days.
[0054] As a result, as disclosed in Figure 6, the size and volume of the tumor were statistically significantly reduced in the group treated with P-cadherin siRNA and SU11274 in combination compared to the group treated with P-cadherin siRNA and SU11274 alone.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of hypopharyngeal or laryngeal cancer comprising, as active ingredients, P-cadherin siRNA which is an oligonucleotide composed of SEQ ID NO. 1 and SEQ ID NO. 2, and SU11274{(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide}. Claim 2 delete Claim 3 delete Claim 4 A pharmaceutical composition for the prevention or treatment of hypopharyngeal cancer or laryngeal cancer according to claim 1, wherein the oligonucleotide P-cadherin siRNA and SU11274{(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide} inhibits the proliferation, migration, and invasion of hypopharyngeal cancer or laryngeal cancer cells. Claim 5 delete Claim 6 A pharmaceutical composition for the prevention or treatment of hypopharyngeal or laryngeal cancer according to claim 1, characterized in that the composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent in addition to the active ingredient. Claim 7 A pharmaceutical composition for the prevention or treatment of hypopharyngeal or laryngeal cancer according to claim 1, characterized in that the composition is prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols. Claim 8 A veterinary composition for the prevention or treatment of hypopharyngeal or laryngeal cancer comprising, as active ingredients, P-cadherin siRNA which is an oligonucleotide composed of SEQ ID NO. 1 and SEQ ID NO. 2, and SU11274{(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide}. Claim 9 A method for the prevention or treatment of hypopharyngeal or laryngeal cancer comprising the step of administering P-cadherin siRNA, which is an oligonucleotide composed of SEQ ID NO. 1 and SEQ ID NO. 2, and SU11274{(3Z)-N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide} to an individual other than a human.
Citation Information
Patent Citations
Use of quinoline derivatives for treating esophageal cancer, and treatment methods, pharmaceutical compositions and kits
JP2019501185A
A biomarker composition for diagnosis of head and neck cancer comprising carboxyl-terminal modulator protein
KR101796091B1
Composition for preventing, improving or treating head and neck cancer comprising moscatilin as effective component
KR1020210129789A
